HFS-14, a specific quality of life scale developed for patients suffering from Hand-foot syndrome

Oncologist

Volumn 16, Issue 10, 2011, Pages 1469-1478

  Sibaud, Vincent ^a   Dalenc, Florence ^a   Chevreau, Christine ^a   Roché, Henri ^a   Delord, Jean Pierre ^a   Mourey, Loïc ^a   Lacaze, Jean Louis ^a   Rahhali, Nora ^b   Taïeb, Charles ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Chemotherapy; Hand foot syndrome; HFS 14 scale; Quality of life; Skindex 16; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; LAPATINIB; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB;

ADULT; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; FEMALE; HAND FOOT SYNDROME; HFS 14 QUESTIONNAIRE; HUMAN; INTERNAL RELIABILITY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; SHORT FORM 12; SKINDEX 16 SCORE; VALIDATION STUDY;

CROSS-SECTIONAL STUDIES; FEMALE; HAND-FOOT SYNDROME; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 80054827513     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0033     Document Type: Review

References (23)

1. Clark AS, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies. Support Cancer Ther 2004;1:213-218.
2. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1:225-234.
3. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-246.
4. Janusch M, Fischer M, Marsch WCh et al. The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16:494-499.
5. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991;24:457-461.
6. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
7. Sibaud V, Delord JP, Chevreau C. Sorafenib-induced hand-foot skin reaction: A Koebner phenomenon? Target Oncol 2009;4:307-310.
8. Yang CH, Lin WC, Chuang CK et al. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
9. Autier J, Escudier B, Wechsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-892.
10. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961.
11. von Moos R, Thuerlimann BJ, Aapro M et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer 2008;44:781-790.
12. Chren MM, Lasek RJ, Sahay AP et al. Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001;5:105-110.
13. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004;9:169-180.
14. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. The Oncologist 2008;13:1001-1011.
15. Seidenberg M, Haltiner A, Taylor MA et al. Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 1994; 16:93-104.
16. Wild D, Grove A, Martin M et al.; ISPOR Task Force for Translation and Cultural Adaptation. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value in Health 2005;8:94-104.
17. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Published August 9, 2006. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, accessed August 16, 2011.
18. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
19. Brazier JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992;305: 160-164.
20. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 4.03, DCTD, NCI, NIH, DHHS. Published on June 14, 2010. Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, accessed August 16, 2011.
21. von Gruenigen V, Frasure H, Fusco N et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010;116:4735-4743.
22. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
23. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-432.